Abstract

Mycoplasma pneumoniae is one of four most common species of organisms that are responsible for most clinically significant infections in humans. It is a frequent cause of acute respiratory infections in both children and adults. The organism can cause pharyngitis, otitis, tracheobronchitis, or community-acquired pneumonia, but patients may also remain totally asymptomatic. Aim of this prospective study for children, was to investigate the association of M. pneumoniae with respiratory tract infections in a Saudi population. This study was designed as a case-control study in which 90 patients (Mean age of the patients in case group was 5.94±2.73 and in control group was 6.51±2.26) of either sexes were included. These patients were classified into two groups: first group (case group), included 45 patients who had been admitted in hospital with diagnosis of respiratory tract infections and the second group (control group), included 45 healthy patients who had no history of respiratory tract infections. Both the groups were age and sex matched. Presence of IgM antibodies to Mycoplasma pneumoniae was assessed by ELISA technique in both groups. In the case group, 4 (9%) cases out of 45 children were positive for anti-mycoplasma antibody whereas in the control group, all children were negative. All positive case group patients had symptoms of acute pneumonia. 18 (40%) of the patients were diagnosed with bronchial asthma (40%) inclusive of all the four cases diagnosed with Mycoplasma pneumoniae infection. The relative risk for the occurrence of mycoplasma infection was estimated to be 9 (95%C.I = 0.49-162.43). However, on comparing the case and control groups, the result was not found to be statistically significant. (Fischer Exact Test p = 0.0583). Children in Saudi Arabia are at a relatively higher risk of developing Mycoplasma pneumoniae infection especially those predisposed with underlying chronic respiratory illnesses such as asthma. This is a first study of its kind from the region reporting such a disease in children using a serological assay as ELISA. Further studies are required to evaluate the risk of coinfection by Mycoplasma pneumoniae, Streptococcus pneumoniae and Chlamydia pneumoniae. Evaluating and establishing a correlation between Mycoplasma pneumoniae and the onset of asthma among infected children can be a prospective field of study for further knowledge of the role of Mycoplasma pneumoniae in chronic respiratory tract infections.

Highlights

  • M. pneumoniae is well known as an important infectious cause for respiratory system and most cases of mycoplasma respiratory infection occur singly or as family outbreaks (Baum, 2004)

  • Children in Saudi Arabia are at a relatively higher risk of developing Mycoplasma pneumoniae infection especially those predisposed with underlying chronic respiratory illnesses such as asthma

  • Further studies are required to evaluate the risk of coinfection by Mycoplasma pneumoniae, Streptococcus pneumoniae and Chlamydia pneumoniae

Read more

Summary

Introduction

M. pneumoniae is well known as an important infectious cause for respiratory system and most cases of mycoplasma respiratory infection occur singly or as family outbreaks (Baum, 2004). This organism is reported to be the most frequent ‘atypical’ pathogen responsible for Community-Acquired Pneumonia (CAP) in children and adults (Hammerschlag, 2001; Thibodeau and Viera, 2004). Osama Mohammed Saed Abdul-Wahab et al / American Journal of Immunology 9 (1): 1-8, 2013 tract infection such as upper respiratory inflammation, bronchitis and a pneumonia, mainly in children and young adults. It has been seems that Mycoplasmae pneumonia and Chlamydia pneumoniae have a more important role in causing both upper and lower respiratory-tract infections than previously thought; they have been associated with wheezing and seem to be frequent in children aged less than 5 years (Hammerschlag, 2000; Esposito et al, 2001; Principi et al, 2001; Esposito et al, 2000)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call